bleomycin + dacarbazine + doxorubicin + vincristine

This is a combination chemotherapy regimen comprising **bleomycin**, **dacarbazine**, **doxorubicin**, and **vincristine**. Each drug is a cytotoxic small molecule used in oncology: - **Bleomycin** is an antibiotic chemotherapy that induces DNA strand breaks primarily by generating free radicals. - **Dacarbazine** is an alkylating agent that inhibits DNA synthesis via methylation. - **Doxorubicin** is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, generating free radicals that damage cellular components. - **Vincristine** is a vinca alkaloid that inhibits microtubule formation in mitosis. Unlike the well-established ABVD regimen (bleomycin + dacarbazine + doxorubicin + vinblastine), the combination with **vincristine** in place of **vinblastine** is not a standard named regimen in the treatment of Hodgkin lymphoma or other cancers based on current guidelines and appears unusual in contemporary clinical use. Each component has a distinct cytotoxic mechanism, and the use together would be classified as multi-agent chemotherapy, but this exact combination does not have a specific, established clinical indication or regimen name.

Brand names

AdriamycinBlenoxaneOncovinDTIC-Dome

Other names

doxorubicin + bleomycin + dacarbazine + vincristine